Healixia is the Belgian community of all professionals active along the life cycle of medicines, medical devices, in vitro diagnostics & other health related products. Members are active in research & development (including pre-clinical, early clinical and later phases), medical affairs, safety, regulatory affairs and market access in industry, academia, investigator sites, authorities, regulatory bodies or in consultancy.

Become a member

Healixia events

  1. compliance (1).jpeg
    15 December '22

    Healixia online conference: Medical Devices

    Online conference.

    This training course is intended for both manufacturers and distributors of medical devices/ in vitro medical devices and will address various questions/issues under the MDR/IVDR.

  2. agenda items (4).jpg
    27 January '23

    Healixia seminar: From CTD to CTR - How to keep Belgium attractive for early phase development in EU

    Diegem

    From January 2023 onwards all clinical trial applications, including phase 1 trials, need to be submitted according to the new Clinical Trial Regulation (CTR). In this meeting, all stakeholders are brought together and given the opportunity to express their perceived challenges and opportunities as we move into this new legislative framework.

  3. agenda items (10).jpg
    02 February '23

    Healixia New Year's Event

    Antwerpen (Wilrijk)

    Join us for an inspirational talk and a networking drink to kick off 2023!

    Keynote: Wellbeing is key for business succes, by Gert Braeken, author of 'Het burn-outvaccin'.

Show all meetings

News

  1. November 29, 2022

    IFAPP Today newsletter - November/December 2022

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of November/December 2022.

    Read more

  2. November 28, 2022

    Medical Affairs survey in collaboration with NVFG

    Fill out the survey aims to map, for the first time in Benelux, the Medical Affairs professional and collect insight on demographics, role & responsibilities, education and other aspects. Target audience are Medical Advisors, Medical Science Liaisons and other Medical Affairs professionals; active in Benelux.

    Read more

  3. November 24, 2022

    Coronavirus: overview of side effects of COVID-19 vaccines from November 24, 2022

    Meldingen van vermoedelijke bijwerkingen hebben bijgedragen tot een betere kennis van het veiligheidsprofiel van deze vaccins. Het FAGG blijft wil de melders bedanken en het melden van ernstige bijwerkingen blijven aanmoedigen om de vaccins beter te kunnen karakteriseren. Het FAGG heeft wel beslist om vanaf 2023 geen cumulatieve overzichten van gemelde bijwerkingen van COVID-19-vaccins meer te publiceren.

    Les notifications d’effets indésirables suspectés, rapportées notamment à l’AFMPS, ont participé à l’amélioration de la connaissance de leur profil de sécurité. L’AFMPS veut remercier les notificateurs et continue d’encourager la notification d’effets indésirables graves afin de mieux les caractériser. L’AFMPS a décidé d’arrêter la publication des aperçus cumulatifs des effets indésirables des vaccins contre la COVID-19 à partir de 2023. 

    Source: FAMHP

    Read more

We thank our partners for their support:

AxTalis_reg access medical_scherm_transparent Brookwood Global-website QbD Group Logo_blue Janssen 440x320 nieuwsbrief